EXPRESSION OF MATRIX METALLOPROTEINASE-2 IN THE MYOCARDIUM IN THE EXPERIMENTAL MODEL OF ANTHRACYCLINE CARDIOMYOPATHY



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The localization and expression of matrix metalloproteinase-2 (MMP-2) in the myocardium and their changes after administration of a sublethal dose (7 mg/kg) of doxorubicin hydrochloride were studied in male Wistar rats (n=28) with the use of an immunohistochemical analysis. MMP-2 in the myocardium of control and experimental animals was detected primarily in cardiomyocyte nuclei. With the development of anthracyclineinduced cardiomyopathy, there was an increase of the index of MMP-2 positive cardiomyocyte nuclei (2.6-fold by the 14th day of the experiment), while MMP-2 expression was also detected in the cardiomyocyte sarcoplasm. Positive correlation between the volume density of cardiomyocytes with lytic sarcoplasmic lesions and the index of MMP-2 positive cardiomyocyte nuclei was detected.

Full Text

Restricted Access

About the authors

Ye. L. Lushnikova

Institute of Molecular Pathology and Pathomorphology (Novosibirsk)

Email: pathol@inbox.ru

D. B. Nikityuk

Institute of Molecular Pathology and Pathomorphology (Novosibirsk)

M. G. Klinnikova

Institute of Molecular Pathology and Pathomorphology (Novosibirsk)

Ye. V. Koldysheva

Institute of Molecular Pathology and Pathomorphology (Novosibirsk)

M. M. Mzhel’skaya

Institute of Molecular Pathology and Pathomorphology (Novosibirsk)

References

  1. Клинникова М. Г., Лушникова Е. Л., Колдышева Е. В. и др. Кардиотоксический и дислипидемический эффекты доксорубицина и амида бетулоновой кислоты // Бюл. экспер. биол. 2016. Т. 162, № 8. С. 247-252.
  2. Непомнящих Л. М., Лушникова Е. Л., Семенов Д. Е. Регенераторно-пластическая недостаточность сердца: Морфологические основы и молекулярные механизмы. М.: Изд-во РАМН, 2003.
  3. Adamcova M., Potacova A., Popelova O. et al. Cardiac remodeling and MMPs on the model chronic daunorubicin-induced cardiomyopathy in rabbits // Physiol. Res. 2010. Vol. 59. P. 831- 836.
  4. Ali M. A., Fan X., Schulz R. Cardiac sarcomeric proteins: Novel intracellular targets of matrix metalloproteinase-2 in heart disease // Trends Cardiovasc. Med. 2011. Vol. 21 (4). P. 112-118.
  5. Aupperle H., Garbade J., Schubert A. et al. Effect of autologous stem cells on immunohistochemical patterns and gene expression of metalloproteinases and their tissue inhibitors in doxorubicin cardiomyopathy in a rabbit model // Vet. Pathol. 2007. Vol. 44 (4). P. 494-503.
  6. Baghirova S., Hughes B. G., Poirier M. et al. Nuclear matrix metalloproteinase-2 in the cardiomyocyte and the ischemic-reperfused heart // J. Mol. Cell. Cardiol. 2016. Vol. 94. P. 153-161.
  7. Bai P., Mabley J. G., Liaudet L. et al. Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity // Oncol. Rep. 2004. Vol. 11, № 2. P. 505-508.
  8. Cheung P.-Y., Sawicki G., Wozniak M. et al. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart // Circulation. 2000. Vol. 101, № 15. P. 1833-1839.
  9. Chow A. K., Cena J., Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature // Br. J. Pharmacol. 2007. Vol. 152, № 2. P. 189-205.
  10. Fan X., Hughes B. G., Ali M. A. et al. Matrix metalloproteinase-2 in oncostatin M-induced sarcomere degeneration in cardiomyocytes // Am. J. Physiol. Heart Circ. Physiol. 2016. Vol. 311, № 1. P. H183-189.
  11. Gao C. Q., Sawicki G., Suarez-Pinzon W. L. et al. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction // Cardiovasc. Res. 2003. Vol. 57, № 2. P. 426-433.
  12. Ivanova M., Dovinova I., Okruhlicova L. et al. Chronic cardiotoxicity of doxorubicin involves activation of myocardial and circulating matrix metalloproteinases in rats // Acta Pharmacol. Sin. 2012. Vol. 33, № 4. P. 459-469.
  13. Jacob-Ferreira A. L., Schulz R. Activation of intracellular matrix metalloproteinase-2 by reactive oxygen-nitrogen species: Consequences and therapeutic strategies in the heart // Arch. Biochem. Biophys. 2013. Vol. 540, № 1-2. P. 82-93.
  14. Kandasamy A. D., Chow A. K., Ali M. A. M., Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: Beyond the matrix // Cardiovasc. Res. 2010. Vol. 85. P. 413-423.
  15. Kwan J. A., Schulze C. J., Wang W. et al. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro // FASEB J. 2004. Vol. 18, № 6. P. 690-692.
  16. Malla N., Sjoli S., Winberg J. O. et al. Biological and pathobiological functions of gelatinase dimersand complexes// Connect. Tissue Res. 2008. Vol. 49. P. 180-184.
  17. Mitry M. A., Edwards J. G. Doxorubicin induced heart failure: Phenotype and molecular mechanisms // Int. J. Cardiol. Heart Vasc. 2016. Vol. 10. P. 17-24.
  18. Spinale F. G. Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function // Physiol. Rev. 2007. Vol. 87, № 4. P. 1285-1342.
  19. Sung M. M., Schulz C. G., Wang W. et al. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury // J. Mol. Cell. Cardiol. 2007. Vol. 43, № 4. P. 429-436.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: № 0110212 от 08.02.1993.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies